{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:31:29Z","timestamp":1773210689025,"version":"3.50.1"},"reference-count":16,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>Meningiomas are frequently occurring, often benign intracranial tumors. Molecular fluorescence can be used to intraoperatively identify residual meningioma tissue and optimize safe resection; however, currently no clinically approved agent is available for this specific tumor type. In meningiomas, vascular endothelial growth factor \u03b1 (VEGF\u03b1) is upregulated, and this biomarker could be targeted with bevacizumab-IRDye800CW, a fluorescent agent that is already clinically applied for the resection of other tumors and neoplasms. Here, the authors investigated the feasibility of using bevacizumab-IRDye800CW to target VEGF\u03b1 in a CH-157MN xenografted mouse model.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>Five mice with CH-157MN xenografts with volumes of 500 mm<jats:sup>3<\/jats:sup> were administered intravenous bevacizumab-IRDye800CW. Mice were imaged in vivo at 24 hours, 48 hours, and 72 hours after injection with the FMT2500 fluorescence imaging system. Biodistribution was determined ex vivo using the Pearl fluorescent imager at 72 hours after injection. To mimic a clinical scenario, 2 animals underwent postmortem xenograft resection using both white-light and fluorescence guidance. Lastly, fresh and frozen human meningioma specimens were incubated ex vivo with bevacizumab-IRDye800CW, stained with anti-VEGF\u03b1, and microscopically examined.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>In vivo, tumors fluoresced at all time points after tracer administration and background fluorescence decreased with time. Ex vivo analyses of tracer biodistribution showed the highest fluorescence in resected tumor tissue. Brain, skull, and muscle tissue showed very low fluorescence. Microscopically, fluorescence was observed in the cytoplasm and was correlated with VEGF\u03b1 expression patterns. During postmortem surgery, both the tumor bulk and a small tumor remnant were detected. Bevacizumab-IRDye800CW bound specifically to all tested human meningioma samples, as indicated by a high fluorescent signal in the tumor bulk compared with the surrounding healthy dura mater.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CONCLUSIONS<\/jats:title>\n<jats:p>Bevacizumab-IRDye800CW showed meningioma specificity, as illustrated by high VEGF\u03b1-mediated uptake in the meningioma xenograft mouse model. Small tumor lesions were detected using fluorescence guidance. Thus, the next step will be to assess the feasibility of using already available clinical grade bevacizumab-IRDye800CW to optimize meningioma resection in a human trial.<\/jats:p>\n<\/jats:sec>","DOI":"10.3171\/2022.9.jns221036","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T19:12:11Z","timestamp":1667416331000},"page":"1263-1272","source":"Crossref","is-referenced-by-count":4,"title":["Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery"],"prefix":"10.3171","volume":"138","author":[{"given":"*Bianca M.","family":"Dijkstra","sequence":"first","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Nonnekens","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"Nagengast","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schelto","family":"Kruijff","sequence":"additional","affiliation":[{"name":"Surgery,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert Jan","family":"Meersma","sequence":"additional","affiliation":[{"name":"Medical Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfred F. A.","family":"den Dunnen","sequence":"additional","affiliation":[{"name":"Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank A. E.","family":"Kruyt","sequence":"additional","affiliation":[{"name":"Medical Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob J. M.","family":"Groen","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1754","reference":[{"issue":"11","key":"b1","series-title":"Neuro Oncol","first-page":"1821","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner R","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD,  EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821\u20131834."},{"issue":"1","key":"b2","series-title":"J Neurol Neurosurg Psychiatry","first-page":"22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson D","year":"1957","unstructured":"Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22\u201339."},{"issue":"3","key":"b3","series-title":"Expert Rev Neurother","first-page":"241","article-title":"Current treatment options for meningioma","volume":"18","author":"Apra C","year":"2018","unstructured":"Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother. 2018;18(3):241\u2013249."},{"issue":"8","key":"b4","series-title":"Acta Neurochir (Wien)","first-page":"1539","article-title":"SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery","volume":"160","author":"Dijkstra BM","year":"2018","unstructured":"Dijkstra BM, Motekallemi A, den Dunnen WFA,  SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery. Acta Neurochir (Wien). 2018;160(8):1539\u20131546."},{"issue":"5","key":"b5","series-title":"Nat Rev Drug Discov","first-page":"391","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara N","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391\u2013400."},{"key":"b6","series-title":"Eur J Pharm Biopharm","first-page":"226","article-title":"Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use","volume":"104","author":"Ter Weele EJ","year":"2016","unstructured":"Ter Weele EJ, Terwisscha van Scheltinga AGT, Linssen MD,  Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use. Eur J Pharm Biopharm. 2016;104:226\u2013234."},{"issue":"13","key":"b7","series-title":"Eur J Nucl Med Mol Imaging","first-page":"4272","article-title":"Targeted optical fluorescence imaging: a meta-narrative review and future perspectives","volume":"48","author":"Schouw HM","year":"2021","unstructured":"Schouw HM, Huisman LA, Janssen YF,  Targeted optical fluorescence imaging: a meta-narrative review and future perspectives. Eur J Nucl Med Mol Imaging. 2021;48(13):4272\u20134292."},{"issue":"5","key":"b8","series-title":"Nat Biomed Eng","first-page":"503","article-title":"Intraoperative imaging in pathology-assisted surgery","volume":"6","author":"Voskuil FJ","year":"2022","unstructured":"Voskuil FJ, Vonk J, van der Vegt B,  Intraoperative imaging in pathology-assisted surgery. Nat Biomed Eng. 2022;6(5):503\u2013514."},{"issue":"2","key":"b9","series-title":"J Neurooncol","first-page":"211","article-title":"Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma","volume":"153","author":"Dijkstra BM","year":"2021","unstructured":"Dijkstra BM, de Jong M, Stroet MCM,  Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma. J Neurooncol. 2021;153(2):211\u2013222."},{"issue":"5","key":"b10","series-title":"J Neurosurg","first-page":"864","article-title":"Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF","volume":"82","author":"Tsai JC","year":"1995","unstructured":"Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg. 1995;82(5):864\u2013873."},{"issue":"1","key":"b11","series-title":"Nat Commun","first-page":"3739","article-title":"Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers","volume":"9","author":"Koller M","year":"2018","unstructured":"Koller M, Qiu SQ, Linssen MD,  Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers. Nat Commun. 2018;9(1):3739."},{"issue":"11","key":"b12","series-title":"J Nucl Med","first-page":"1778","article-title":"Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies","volume":"52","author":"Terwisscha van Scheltinga AGT","year":"2011","unstructured":"Terwisscha van Scheltinga AGT, van Dam GM, Nagengast WB,  Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 2011;52(11):1778\u20131785."},{"issue":"3","key":"b13","series-title":"J Nucl Med","first-page":"480","article-title":"Molecular fluorescence endoscopy targeting vascular endothelial growth factor A for improved colorectal polyp detection","volume":"57","author":"Tjalma JJ","year":"2016","unstructured":"Tjalma JJ, Garcia-Allende PB, Hartmans E,  Molecular fluorescence endoscopy targeting vascular endothelial growth factor A for improved colorectal polyp detection. J Nucl Med. 2016;57(3):480\u2013485."},{"issue":"11","key":"b14","series-title":"Cancer Res","first-page":"3347","article-title":"Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake","volume":"73","author":"Arjaans M","year":"2013","unstructured":"Arjaans M, Oude Munnink TH, Oosting SF,  Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 2013;73(11):3347\u20133355."},{"key":"b15","series-title":"J Surg Res","first-page":"145","article-title":"Anti-claudin-1 conjugated to a near-infrared fluorophore targets colon cancer in PDOX mouse models","volume":"242","author":"Hollandsworth HM","year":"2019","unstructured":"Hollandsworth HM, Lwin TM, Amirfakhri S,  Anti-claudin-1 conjugated to a near-infrared fluorophore targets colon cancer in PDOX mouse models. J Surg Res. 2019;242:145\u2013150."},{"issue":"11","key":"b16","series-title":"PLoS One","first-page":"e8051","article-title":"Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice","volume":"4","author":"Zhou H","year":"2009","unstructured":"Zhou H, Luby-Phelps K, Mickey BE, Habib AA, Mason RP, Zhao D. Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice. PLoS One. 2009;4(11):e8051."}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/138\/5\/article-p1263.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/138\/5\/article-p1263.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/138\/5\/article-p1263.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T13:16:18Z","timestamp":1732194978000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/138\/5\/article-p1263.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":16,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.3171\/2022.9.jns221036","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}